Brent Pfeiffenberger, Pharm.D., MBA, is the Chief Operating Officer at Neogene Therapeutics. At Neogene, Dr. Pfeiffenberger oversees the company’s global business operations. Before joining Neogene, Dr. Pfeiffenberger most recently served as senior vice president, U.S. Oncology, at Bristol Myers Squibb where he oversaw an extensive oncology portfolio. Prior to that, Dr. Pfeiffenberger held several critical business leadership roles – both within and outside the U.S. at Bristol Myers Squibb – where he built, led and evolved commercial operations. He previously served as general manager of Australia/New Zealand and led the Worldwide Commercial Oncology Organization, where he closely partnered with the Research and Development team on the creation and delivery of global development strategies for a large-scale oncology program. Dr. Pfeiffenberger received his Pharm.D. from Duquesne University and his MBA from the Wharton School of Business at the University of Pennsylvania.